None of the 29 investors followed here reported a position in PHG in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Alan Armstrong Sen. OK | 1 | +$8.0K | Bought Mar 30, 26 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Mar 30, 26 | Alan Armstrong Sen. OK | Self | Buy | $1,001 - $15,000 | Jul 21, 26 (113d) | Report |
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for PHG.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.0 | 11.5 | -14.4 | -3.9 | 0.2 | 3.0 | -3.3 | 1.0 | -8.1 | 1.5 | −8.5% | ||
| 2025 | 8.9 | -5.6 | -2.4 | -0.2 | -9.1 | 4.1 | 9.3 | 5.3 | -1.2 | 0.2 | 3.1 | -3.8 | +7.0% |
| 2024 | -9.4 | -5.1 | -0.2 | 32.7 | 2.2 | -7.1 | 11.8 | 7.1 | 8.5 | -19.9 | 4.0 | -7.0 | +8.5% |
| 2023 | 14.2 | -4.6 | 12.4 | 15.1 | -10.6 | 14.9 | -4.5 | 7.8 | -10.7 | -4.9 | 7.7 | 14.3 | +55.6% |
| 2022 | -9.7 | 2.4 | -10.4 | -15.6 | 0.6 | -17.0 | -3.7 | -20.1 | -7.2 | -17.8 | 18.9 | -0.3 | −59.3% |
| 2021 | 0.2 | 0.2 | 4.8 | -0.7 | -0.3 | -12.0 | -7.4 | 0.2 | -3.7 | 6.3 | -25.5 | 4.7 | −32.0% |
| 2020 | -6.2 | -6.3 | -6.4 | 9.3 | 3.5 | 3.0 | 10.5 | -8.2 | -0.7 | -1.4 | 10.8 | 5.1 | +11.0% |
| 2019 | 12.3 | 0.7 | 2.9 | 5.2 | -7.9 | 10.0 | 7.4 | 0.6 | -2.0 | -4.8 | 5.9 | 5.0 | +39.0% |
| 2018 | 7.8 | -6.6 | 0.7 | 10.2 | -2.6 | 2.7 | 3.7 | 1.8 | 2.0 | -18.2 | 1.9 | -7.5 | −7.1% |
| 2017 | -3.9 | 3.1 | 6.0 | 7.2 | 2.6 | 1.4 | 6.6 | -0.5 | 8.4 | -1.0 | -5.0 | -2.4 | +23.7% |
| 2016 | 4.8 | -5.1 | 12.7 | -3.6 | -2.1 | -7.4 | 6.5 | 9.0 | 2.2 | 1.5 | -4.7 | 6.9 | +20.1% |
| 2015 | -4.9 | 8.5 | -5.3 | 1.0 | -4.6 | -6.7 | 9.2 | -7.8 | -8.5 | 14.8 | 1.1 | -6.5 | −12.2% |
| 2014 | -6.1 | 0.4 | 0.9 | -9.1 | -1.3 | 0.7 | -3.0 | -0.9 | 3.9 | -11.9 | 7.6 | -3.5 | −21.6% |
| 2013 | 17.1 | -9.0 | 4.4 | -6.6 | 2.4 | -3.8 | 16.9 | -3.1 | 4.6 | 9.8 | 1.0 | 3.4 | +39.3% |
| 2012 | -3.3 | 3.6 | -3.0 | -1.8 | -11.0 | 10.5 | 11.9 | 3.9 | 2.5 | 7.0 | 3.2 | 2.6 | +26.7% |
| 2011 | 1.7 | 4.7 | -1.6 | -8.3 | -5.5 | -7.8 | -3.5 | -14.5 | -15.3 | 16.2 | -2.5 | 3.0 | −31.8% |
| 2010 | 2.7 | -3.1 | 9.3 | 4.1 | -10.6 | 0.1 | 4.3 | -10.3 | 12.2 | -2.8 | -11.0 | 13.3 | +4.3% |
| 2009 | -8.5 | -12.1 | -7.0 | 20.9 | 5.4 | -2.8 | 23.6 | -0.9 | 8.0 | 3.0 | 9.4 | 7.2 | +48.2% |
| 2008 | -7.8 | -1.2 | -1.5 | -2.0 | 2.3 | -12.0 | -1.5 | -2.6 | -15.9 | -32.1 | -11.5 | 21.4 | −53.5% |
| 2007 | 4.2 | -6.2 | 3.8 | 7.7 | 3.4 | -0.2 | -4.5 | -2.1 | 13.6 | -8.0 | 0.7 | 2.7 | +13.8% |
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. Koninklijke Philips N.V. has strategic alliance with WellSpan Health to advanced imaging and diagnostics technology products and platforms. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Buy / hold / sell counts